Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo‐controlled clinical trial

Abstract Background Heart disease is an important cause of morbidity and mortality in cats, but there is limited evidence of the benefit of any medication. Hypothesis The angiotensin‐converting enzyme inhibitor benazepril would delay the time to treatment failure in cats with heart disease of variou...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jonathan N. King, Mike Martin, Valérie Chetboul, Luca Ferasin, Anne T. French, Günther Strehlau, Wolfgang Seewald, Sarah G. W. Smith, Simon T. Swift, Susan L. Roberts, Andrea M. Harvey, Christopher J. L. Little, Sarah M. A. Caney, Kerry E. Simpson, Andrew H. Sparkes, Eleanor J. Mardell, Eric Bomassi, Claude Muller, John P. Sauvage, Armelle Diquélou, Matthias A. Schneider, Laurence J. Brown, David D. Clarke, Jean‐Francois Rousselot
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Oxford University Press 2019-11-01
coleção:	Journal of Veterinary Internal Medicine
Assuntos:	ACE inhibitor survival treatment failure
Acesso em linha:	https://doi.org/10.1111/jvim.15572
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!